UK markets closed
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • FTSE 250

    20,961.31
    -334.92 (-1.57%)
     
  • AIM

    1,163.26
    -10.13 (-0.86%)
     
  • GBP/EUR

    1.1616
    +0.0019 (+0.17%)
     
  • GBP/USD

    1.3839
    -0.0055 (-0.40%)
     
  • BTC-GBP

    35,046.18
    -146.69 (-0.42%)
     
  • CMC Crypto 200

    970.13
    +26.95 (+2.86%)
     
  • S&P 500

    3,807.13
    +38.66 (+1.03%)
     
  • DOW

    31,258.59
    +334.45 (+1.08%)
     
  • CRUDE OIL

    66.08
    +2.25 (+3.52%)
     
  • GOLD FUTURES

    1,696.00
    -4.70 (-0.28%)
     
  • NIKKEI 225

    28,864.32
    -65.79 (-0.23%)
     
  • HANG SENG

    29,098.29
    -138.50 (-0.47%)
     
  • DAX

    13,920.69
    -135.65 (-0.97%)
     
  • CAC 40

    5,782.65
    -48.00 (-0.82%)
     

Fresenius Medical Care AG & Co. KGaA anticipates significant negative impact on 2021 net income due to accelerated impact of Covid-19 related excess mortality on its patient population

·2-min read

Fresenius Medical Care AG & Co. KGaA / Key word(s): Forecast
Fresenius Medical Care AG & Co. KGaA anticipates significant negative impact on 2021 net income due to accelerated impact of Covid-19 related excess mortality on its patient population

01-Feb-2021 / 22:35 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Fresenius Medical Care AG & Co. KGaA anticipates significant negative impact on 2021 net income due to accelerated impact of Covid-19 related excess mortality on its patient population

Based on preliminary numbers Fresenius Medical Care confirms achievement of its 2020 financial targets, with net income (attributable to shareholders of Fresenius Medical Care AG & Co. KGaA) slightly above the top end of the target range. Earnings development was impacted negatively in Q4 by an impairment in the Latin America segment of approximately EUR 195 million, which is treated as a special item.

Fresenius Medical Care hereby informs the market early on its indicative preliminary assumptions for the development of the net income in fiscal year 2021.

The significant acceleration in November and December 2020 of Covid-19 related patient excess mortality is expected to continue into 2021. In addition, the Company anticipates the associated cost for safety measures for patients and employees to remain at a high level. Fresenius Medical Care continues to monitor the further development of mortality, the adoption and speed of roll out of vaccinations as well as government relief measures and to closely evaluate opportunities to adjust its cost base.

Against this backdrop, Fresenius Medical Care anticipates, based on early indications and before special items, such as potential restructuring measures, and on a constant currency basis, revenue growth of up to mid-single digits and assumes net income (attributable to shareholders of Fresenius Medical Care AG & Co. KGaA) to decline by up to 25 percent.

The mid-term targets through 2025, as defined in October 2020, remain unchanged.

Contact:
Dr. Dominik Heger
Head of Investor Relations, Strategic Development & Communications | EVP
dominik.heger@fmc-ag.com
P. +49 6172 609 2601

01-Feb-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Fresenius Medical Care AG & Co. KGaA

Else-Kröner-Straße 1

61352 Bad Homburg

Germany

Phone:

+49 (0) 6172- 609 2525

Fax:

+49 (0) 6172- 609 2301

E-mail:

ir@fmc-ag.com

Internet:

www.freseniusmedicalcare.com

ISIN:

DE0005785802

WKN:

578580

Indices:

DAX

Listed:

Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; NYSE, Luxembourg Stock Exchange

EQS News ID:

1164987


 

End of Announcement

DGAP News Service

show this
show this